A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer

BACKGROUND: AT-101 is a BCL-2 Homolog domain 3 mimetic previously demonstrated to have tumoricidal effects in advanced solid organ malignancies. Given the evidence of activity in xenograft models, treatment with AT-101 in combination with docetaxel is a therapeutic doublet of interest in metastatic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Swiecicki, Paul L., Bellile, Emily, Sacco, Assuntina G., Pearson, Alexander T., Taylor, Jeremy M. G., Jackson, Trachette L., Chepeha, Douglas B., Spector, Matthew E., Shuman, Andrew, Malloy, Kelly, Moyer, Jeffrey, McKean, Erin, McLean, Scott, Sukari, Ammar, Wolf, Gregory T., Eisbruch, Avraham, Prince, Mark, Bradford, Carol, Carey, Thomas E., Wang, Shaomeng, Nör, Jacques E., Worden, Francis P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5036856/
https://ncbi.nlm.nih.gov/pubmed/27225873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0364-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados